Stock of BridgeBio Pharma, Inc. (BBIO) gained 4 percent on Thursday after the company announced that it will receive strategic financing of up to $1.25 billion from Blue Owl Capital and Canada Pension Plan Investment Board, a subsidiary of CPPIB Credit Investments Inc.
Currently, BridgeBio's stock is moving up 4.19 percent to $38.46 over the previous close of $36.91 on a volume of 766,322. It had traded between $7.94 and $44.32 in the past 52-week period.
The proposed financing comprises of $500 million in cash from Blue Owl and CPP Investments. Additionally, Blue Owl will provide a credit facility of $450 million and additional incremental facilities of up to $300 million, the company stated.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.